1,466 reports of this reaction
2.8% of all OXYBUTYNIN reports
#3 most reported adverse reaction
FALL is the #3 most commonly reported adverse reaction for OXYBUTYNIN, manufactured by Allergan, Inc.. There are 1,466 FDA adverse event reports linking OXYBUTYNIN to FALL. This represents approximately 2.8% of all 51,990 adverse event reports for this drug.
OXYBUTYNIN has an overall safety score of 78 out of 100. Patients taking OXYBUTYNIN who experience fall should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FALL is a less commonly reported adverse event for OXYBUTYNIN, but still significant enough to appear in the safety profile.
In addition to fall, the following adverse reactions have been reported for OXYBUTYNIN:
The following drugs have also been linked to fall in FDA adverse event reports:
FALL has been reported as an adverse event in 1,466 FDA reports for OXYBUTYNIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FALL accounts for approximately 2.8% of all adverse event reports for OXYBUTYNIN, making it one of the most commonly reported side effect.
If you experience fall while taking OXYBUTYNIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.